|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
||||||||||||||||||
|
|
|||||||||||||||||
1. Identity of the issuer or the underlying issuer |
Circassia Pharmaceuticals Plc |
|||||||||||||||||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||||||||||||||||
An acquisition or disposal of voting rights |
|
|||||||||||||||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
X |
|||||||||||||||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||||||||||||||||
An event changing the breakdown of voting rights |
|
|||||||||||||||||
Other (please specify): |
|
|
||||||||||||||||
3. Full name of person(s) subject to the |
ODEY ASSET MANAGEMENT LLP |
|||||||||||||||||
4. Full name of shareholder(s) |
|
|||||||||||||||||
5. Date of the transaction and date on |
13 MARCH 2014 |
|||||||||||||||||
6. Date on which issuer notified: |
14 MARCH 2014 |
|||||||||||||||||
7. Threshold(s) that is/are crossed or |
12% |
|||||||||||||||||
8. Notified details: |
||||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||||||||||
Ordinary Share (GB00B0CGR828) |
|
|
22,500,000 |
22,500,000 |
|
12.00% |
|
|||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||||
|
|
|
|
|
||||||||||||||
|
||||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|||||||||||||
|
|
|
|
|
|
|
||||||||||||
|
||||||||||||||||||
Total (A+B+C) |
||||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||||
Ordinary Shares |
12.00% |
|||||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||||||||||||||||||
Odey European Inc. Fund holds 3.79%. All other funds hold less than 3%.
|
||||||||||||||||||
|
||||||||||||||||||
Proxy Voting: |
||||||||||||||||||
10. Name of the proxy holder: |
|
|||||||||||||||||
11. Number of voting rights proxy holder will cease |
|
|||||||||||||||||
12. Date on which proxy holder will cease to hold |
|
|||||||||||||||||
|
||||||||||||||||||
|
|
|||||||||||||||||
14. Contact name: |
Julien Cotta Chief Financial Officer |
|||||||||||||||||
15. Contact telephone number: |
+44 (0) 1865 405560 |
|||||||||||||||||